Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Mei L, Du W, Idowu M, von Mehren M, Boikos SA.

Front Oncol. 2018 May 7;8:135. doi: 10.3389/fonc.2018.00135. eCollection 2018. Review.

2.

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2018 May;16(5):536-563. doi: 10.6004/jnccn.2018.0025.

PMID:
29752328
3.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

PMID:
29710216
4.

Granular cell tumor experience at a comprehensive cancer center.

Moten AS, Movva S, von Mehren M, Wu H, Esnaola NF, Reddy SS, Farma JM.

J Surg Res. 2018 Jun;226:1-7. doi: 10.1016/j.jss.2018.01.027. Epub 2018 Feb 9.

PMID:
29661274
5.

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.

Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA.

Int J Mol Sci. 2018 Mar 4;19(3). pii: E732. doi: 10.3390/ijms19030732.

6.

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, Dinner S, Folbrecht J, Frazier AL, Goldsby R, Gubin A, Hayashi R, Huang MS, Link MP, Livingston JA, Matloub Y, Millard F, Oeffinger KC, Puccetti D, Reed D, Robinson S, Rosenberg AR, Sanft T, Spraker-Perlman HL, von Mehren M, Wechsler DS, Whelan KF, Yeager N, Gurski LA, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):66-97. doi: 10.6004/jnccn.2018.0001.

PMID:
29295883
7.

Gastrointestinal Stromal Tumors.

von Mehren M, Joensuu H.

J Clin Oncol. 2018 Jan 10;36(2):136-143. doi: 10.1200/JCO.2017.74.9705. Epub 2017 Dec 8.

PMID:
29220298
8.

Emerging drugs for the treatment of gastrointestinal stromal tumour.

Kasireddy V, von Mehren M.

Expert Opin Emerg Drugs. 2017 Dec;22(4):317-329. doi: 10.1080/14728214.2017.1411479. Epub 2017 Dec 18.

PMID:
29183145
9.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M.

Invest New Drugs. 2018 Jun;36(3):476-486. doi: 10.1007/s10637-017-0546-9. Epub 2017 Nov 27.

PMID:
29177975
10.

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis.

Meeker CR, Wong YN, Egleston BL, Hall MJ, Plimack ER, Martin LP, von Mehren M, Lewis BR, Geynisman DM.

J Natl Compr Canc Netw. 2017 Oct;15(10):1224-1233. doi: 10.6004/jnccn.2017.0161.

PMID:
28982748
11.

Randomized Clinical Trials in Gastrointestinal Stromal Tumors.

Liu Y, von Mehren M.

Surg Oncol Clin N Am. 2017 Oct;26(4):545-557. doi: 10.1016/j.soc.2017.05.004. Epub 2017 Aug 4. Review.

PMID:
28923219
12.

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.

Belinsky MG, Cai KQ, Zhou Y, Luo B, Pei J, Rink L, von Mehren M.

BMC Cancer. 2017 Aug 2;17(1):512. doi: 10.1186/s12885-017-3499-7. Review.

13.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

PMID:
28651804
14.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728.

15.

Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00014. Epub 2017 Aug 15.

16.

Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.

Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, Pacak K, Stratakis CA, Helman LJ, La Quaglia MP.

J Clin Oncol. 2017 Feb 10;35(5):523-528. doi: 10.1200/JCO.2016.68.6733. Epub 2016 Dec 28.

17.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH.

Cancer. 2017 Jan 1;123(1):90-97. doi: 10.1002/cncr.30379. Epub 2016 Oct 3.

18.

Efficacy of trabectedin for the treatment of liposarcoma.

Zijoo R, von Mehren M.

Expert Opin Pharmacother. 2016 Oct;17(14):1953-62. doi: 10.1080/14656566.2016.1229304. Epub 2016 Sep 15. Review.

PMID:
27615729
19.

Management of Gastrointestinal Stromal Tumors.

von Mehren M.

Surg Clin North Am. 2016 Oct;96(5):1059-75. doi: 10.1016/j.suc.2016.05.011. Review.

PMID:
27542643
20.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

PMID:
27371698
21.

Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.

Zook P, Pathak HB, Belinsky MG, Gersz L, Devarajan K, Zhou Y, Godwin AK, von Mehren M, Rink L.

Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.

22.

Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer.

Meeker CR, Geynisman DM, Egleston BL, Hall MJ, Mechanic KY, Bilusic M, Plimack ER, Martin LP, von Mehren M, Lewis B, Wong YN.

J Oncol Pract. 2016 Jul;12(7):e755-64. doi: 10.1200/JOP.2016.011049. Epub 2016 Jun 21.

23.

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J.

J Natl Compr Canc Netw. 2016 Jun;14(6):758-86.

PMID:
27283169
24.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.

Eur J Cancer. 2016 Jul;61:94-101. doi: 10.1016/j.ejca.2016.03.076. Epub 2016 May 5.

25.

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, Trent JC, von Mehren M, Wright JA, Schiffman JD, Raygada M, Pacak K, Meltzer PS, Miettinen MM, Stratakis C, Janeway KA, Helman LJ.

JAMA Oncol. 2016 Jul 1;2(7):922-8. doi: 10.1001/jamaoncol.2016.0256.

26.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.

Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH.

Cancer. 2016 Mar 15;122(6):868-74. doi: 10.1002/cncr.29858. Epub 2015 Dec 28.

27.

Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.

Belinsky MG, Rink L, Cai KQ, Capuzzi SJ, Hoang Y, Chien J, Godwin AK, von Mehren M.

BMC Cancer. 2015 Nov 10;15:887. doi: 10.1186/s12885-015-1872-y.

28.

Patterns of Chemotherapy Administration in High-Risk Soft Tissue Sarcoma and Impact on Overall Survival.

Movva S, von Mehren M, Ross EA, Handorf E.

J Natl Compr Canc Netw. 2015 Nov;13(11):1366-74.

PMID:
26553766
29.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR.

J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.

30.

Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.

Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA.

Oncotarget. 2015 May 20;6(14):12234-47.

31.

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB.

Cancer Chemother Pharmacol. 2015 May;75(5):1047-55. doi: 10.1007/s00280-015-2705-z. Epub 2015 Mar 20.

32.

Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, Godwin AK.

Mol Cancer Ther. 2014 Oct;13(10):2276-87. doi: 10.1158/1535-7163.MCT-14-0043. Epub 2014 Aug 13.

33.

Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.

Chun YS, Huang M, Rink L, Von Mehren M.

World J Surg Oncol. 2014 Jul 22;12:231. doi: 10.1186/1477-7819-12-231.

34.

Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancer.

Cole M, Parajuli S, Laske D, Goldstein L, Morrison T, Mukherjee A, Tumelty K, Tetzlaff E, von Mehren M, Inniss S.

Am J Case Rep. 2014 Jul 10;15:294-9. doi: 10.12659/AJCR.890656. eCollection 2014.

35.

GIST treatment options after tyrosine kinase inhibitors.

Songdej N, von Mehren M.

Curr Treat Options Oncol. 2014 Sep;15(3):493-506. doi: 10.1007/s11864-014-0295-3. Review.

PMID:
24952730
36.

Gastrointestinal stromal tumors, version 2.2014.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):853-62.

PMID:
24925196
37.

Challenges in the treatment of angiosarcoma: a single institution experience.

Singla S, Papavasiliou P, Powers B, Gaughan J, von Mehren M, Watson JC, Farma JM.

Am J Surg. 2014 Aug;208(2):254-9. doi: 10.1016/j.amjsurg.2014.01.007. Epub 2014 Apr 15.

PMID:
24811931
38.

Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging.

Hensley H, Devarajan K, Johnson JR, Piwnica-Worms D, Godwin AK, von Mehren M, Rink L.

Cancer Biol Ther. 2014 Jul;15(7):911-8. doi: 10.4161/cbt.28880. Epub 2014 Apr 22.

39.

Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas.

Shaker M, Pascarelli KM, Plantinga MJ, Love MA, Lazar AJ, Ingram DR, von Mehren M, Lev D, Kipling D, Broccoli D.

Biomark Cancer. 2014 Apr 6;6:1-10. doi: 10.4137/BIC.S14683. eCollection 2014.

40.

Soft tissue sarcoma, version 2.2014.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, Delaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Apr;12(4):473-83.

PMID:
24717567
41.

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.

Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27.

42.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.

J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Oct 20;32(30):3462.

43.

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.

von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S.

Invest New Drugs. 2014 Jun;32(3):518-25. doi: 10.1007/s10637-014-0064-y. Epub 2014 Jan 24.

44.

Adolescent and young adult oncology, version 2.2014.

Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, Frazier AL, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack B, Shead DA, Sundar H.

J Natl Compr Canc Netw. 2014 Jan;12(1):21-32; quiz 32.

PMID:
24453290
45.

Head and neck sarcomas: a comprehensive cancer center experience.

Tejani MA, Galloway TJ, Lango M, Ridge JA, von Mehren M.

Cancers (Basel). 2013 Jul 15;5(3):890-900. doi: 10.3390/cancers5030890.

46.

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

Vadakara J, von Mehren M.

Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20. doi: 10.1016/j.hoc.2013.07.007. Review.

47.

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.

Ann Surg. 2013 Sep;258(3):422-9. doi: 10.1097/SLA.0b013e3182a15eb7.

48.

Bone cancer.

Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H; National complrehensive cancer network.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):688-723.

PMID:
23744868
49.

Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.

Belinsky MG, Rink L, von Mehren M.

Front Oncol. 2013 May 17;3:117. doi: 10.3389/fonc.2013.00117. eCollection 2013.

50.

Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.

Plantinga MJ, Pascarelli KM, Merkel AS, Lazar AJ, von Mehren M, Lev D, Broccoli D.

Mol Cancer Res. 2013 Jun;11(6):557-67. doi: 10.1158/1541-7786.MCR-13-0013. Epub 2013 Mar 15.

Supplemental Content

Loading ...
Support Center